Blog

Effector functions drive antibody impact. Biointron reviews ADCC, CDC, and other mechanisms that enable antibodies to protect health and guide new therapies.

Clear intellectual property policies foster biotech growth. Biointron shows how no-royalty models encourage innovation, collaboration, and therapeutic progress.

Genetic variations create antibody allotypes. Biointron highlights their implications for immunology, clinical studies, and therapeutic antibody development.

Explore antibody isotypes (IgA, IgD, IgE, IgG, IgM), their structural differences, immune functions, and why IgG plays a key role in long-term protective immunity.

Antibody production can be in vivo or in vitro. Biointron compares these methods, highlighting efficiency, scalability, and suitability for different applications.

Antibody structure defines function. Biointron explains domains, antigen binding, and immune mechanisms that make antibodies vital for health and therapeutics.

Transgenic mouse models enable humanized antibody discovery. Biointron explains why they are essential tools for generating next-generation therapeutics.

Discover the evolution of antibody research, from early inoculation methods to advanced monoclonal antibody therapies that have transformed immunology and modern medicine.

Discover how phage display technology enables high-throughput screening of antibodies, peptides, and therapeutic proteins to accelerate drug discovery and protein engineering.

Compare in vivo vs in vitro methods: definitions, advantages, limitations, and when to use each across drug discovery, ADME/PK-PD, and clinical translation.

Discover the unique properties and clinical potential of multispecific antibodies, including tetraspecific formats, advancing next-generation therapeutic strategies.

Microfluidic technology is transforming biotechnology. Biointron shows how microfluidics enhance antibody research with precision, speed, and innovative applications.